Trials / Unknown
UnknownNCT00608075
Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- University of Cincinnati · Academic / Other
- Sex
- All
- Age
- 15 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving lithium, an FDA-approved treatment for bipolar mania, in order to better understand who benefits from treatment and why they respond to medications. Studying this may help improve treatment and outcome in patients with bipolar disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lithium | 600 mg - 1800 mg per day |
| DRUG | Lithium | 600 - 1800 mg |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2015-07-01
- Completion
- 2017-07-01
- First posted
- 2008-02-06
- Last updated
- 2016-10-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00608075. Inclusion in this directory is not an endorsement.